Object. To determine the feasibility, toxicity, and potential therapeutic benefits of systemic adoptive immunotherapy, 10 patients with progressive primary or recurrent malignant glioma received this treatment. Adoptive immunotherapy, the transfer of immune T lymphocytes, is capable of mediating the regression of experimental brain tumors in animal models. In animal models, lymph nodes (LNs) that drain the tumor vaccine site are a rich source of tumor-immune T cells.
Methods. In this clinical study, patients were inoculated intradermally with irradiated autologous tumor cells and granulocyte macrophage-colony stimulating factor as an adjuvant. Cells from draining inguinal LNs, surgically resected 7 days after vaccination, were stimulated sequentially with staphylococcal enterotoxin A and anti-CD3, and a low dose of interleukin-2 (60 IU/ml) was used to expand the stimulated cells. The maximum cell proliferation was 350-fold over 10 days of culture. The activated cells were virtually all T cells consisting of various proportions of CD4 and CD8 cells. These cells were given to patients by intravenous infusion at doses ranging from 9 × 108 to 1.5 × 1011. There were no Grade 3 or 4 toxicities associated with the treatment. Following T-cell transfer therapy, radiographic regression that lasted at least 6 months was demonstrated in two patients with recurrent tumors. One patient demonstrated stable disease that has lasted for more than 17 months. The remaining patients had progressive disease; however, four of the eight patients with recurrent tumor remain alive more than 1 year after surgery for recurrence. Three patients required intervention with corticosteroid agents or additional surgery approximately 1 month following cell transfer.
Conclusions. These intriguing clinical observations warrant further trials to determine whether this approach can provide therapeutic benefits and improve survival.
AlexanderJPKudohSMelsopKAet al: T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.Cancer Res53:1380–13871993Cancer Res 53:
BremHPiantadosiSBurgerPCet al: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas.Lancet345:1008–10121995Lancet 345:
BrooksWHNetskyMGNormansellDEet al: Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor.J Exp Med136:1631–16471972J Exp Med 136:
ChouTChangAEShuS: Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity.J Immunol140:2453–24611988J Immunol 140:
FakhraiHDorigoOShawlerDLet al: Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy.Proc Natl Acad Sci USA93:2909–29141996Proc Natl Acad Sci USA 93:
FinkeJHZeaAHStanleyJet al: Loss of T-cell receptor ζ chain and p56lck in T-cells infiltrating human renal cell carcinoma.Cancer Res53:5613–56161993lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 53:
GoedegebuurePSDouvilleLMLiHet al: Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.J Clin Oncol13:1939–19491995J Clin Oncol 13:
HayesRLKoslowMHiesigerEMet al: Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.Cancer76:840–8521995Cancer 76:
KruseCASchiltzPMBellgrauDet al: Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors.J Neurooncol19:161–1681994J Neurooncol 19:
MahaleyMSJrBrooksWHRoszmanTLet al: Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients.J Neurosurg46:467–4761977J Neurosurg 46:
MaxwellMGalanopoulosTNeville-GoldenJet al: Effect of the expression of transforming growth factor-β2 in primary human glioblastomas on immunosuppression and loss of immune surveillance.J Neurosurg76:799–8041992J Neurosurg 76:
MedawarPW: Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye.Br J Exp Pathol29:58–691948Br J Exp Pathol 29:
MerchantREMerchantLHCookSHSet al: Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor.Neurosurgery23:725–7321988Neurosurgery 23:
RosenbergSAPackardBSAebersoldPMet al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.N Engl J Med319:1675–16801988N Engl J Med 319:
RoszmanTLBrooksWH: Immunobiology of primary intracranial tumors. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumors.Clin Exp Immunol39:395–4021980Clin Exp Immunol 39:
SawamuraYHosokawaMKuppnerMCet al: Antitumor activity and surface phenotypes of human glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin 2.Cancer Res49:1843–18491989Cancer Res 49:
ShuSKrinockRAMatsumuraTet al: Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.J Immunol152:1277–12881994J Immunol 152:
SimonsJWJaffeeEMWeberCEet al: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.Cancer Res57:1537–15461997Cancer Res 57:
YoshidaSTanakaRTakaiNet al: Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.Cancer Res48:5011–50161988Cancer Res 48: